ZBH Stock Recent News

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions record year-over-year sales growth at CER.

Zimmer Biomet Holdings Inc. (NYSE:ZBH ) Q4 2022 Earnings Conference Call February 3, 2023 8:30 AM ET Company Participants Bryan Hanson - President, Chief Executive Officer Suketu Upadhyay - Executive Vice President, Chief Financial Officer Ivan Tornos - Chief Operating Officer Keri Mattox - Senior Vice President, Chief Communications and Administration Officer Conference Call Participants Ryan Zimmerman - BTIG Mike Matson - Needham & Co. Larry Biegelsen - Wells Fargo Travis Steed - Bank of America Drew Ranieri - Morgan Stanley Josh Jennings - Cowen Robbie Marcus - JP Morgan Jayson Bedford - Raymond James Kyle Rose - Canaccord Genuity Chris Pasquale - Nephron Rick Wise - Stifel Operator Good morning ladies and gentlemen and welcome to the Zimmer Biomet fourth quarter 2022 earnings conference call. If anyone needs assistance at any time during the conference, please press the star followed by the zero.

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) reported a beat on both the top and bottom lines when it delivered its fourth quarter 2022 earnings report on February 3. The surgical appliance and supply company delivered quarterly net sales of $1.83 billion.

Zimmer (ZBH) delivered earnings and revenue surprises of 2.73% and 3.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zimmer Biomet Holdings (NYSE: ZBH) is set to report Q4'22 results on Feb 3, and there are a few things that investors should keep an eye out for.The company is expected to have experienced continued recovery in its legacy business in Q422, driven by strong elective procedure recovery and commercial execution within the knee and hip businesses.

Zimmer Biomet (ZBH) is expected to have witnessed continued recovery in its legacy business in the fourth quarter, despite the choppy market situation.

Zimmer Biomet has been struggling, or better said, stagnating for years. Lack of progress has pretty much been the case since the tie-up between Zimmer and Biomet.

Investors are optimistic about Zimmer Biomet (ZBH) owing to ongoing business recovery from the COVID-led pandemic impact.

Zimmer Biomet (ZBH) continues to face significant challenges in terms of unfavorable foreign exchange, supply, inflation and staffing shortage.